Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CEL | P19835 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8139831 | 1.00 | CEL (0.32) | CELDAOCYP11B2 | |
| SCHEMBL1607953 | 0.98 | — | — | |
| SCHEMBL8133889 | 0.93 | — | — | |
| SCHEMBL454996 | 0.79 | DAO (0.34) | DAO | |
| SCHEMBL7442542 | 0.69 | — | — | |
| SCHEMBL1777152 | 0.65 | CEL (0.38) | CELCYP11B2 | |
| SCHEMBL5581551 | 0.64 | TDO2 (0.34) | CELDAOCYP11B2 | |
| SCHEMBL7854146 | 0.62 | CEL (0.32) | CELDAOCYP11B2 | |
| SCHEMBL7853379 | 0.62 | CEL (0.32) | CELDAOCYP11B2 | |
| SCHEMBL7853249 | 0.62 | CEL (0.32) | CELDAOCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0276700-A1 | 8-Cyano-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids, process for their preparation, and antibacterial agents containing them | BAYER AG (DE) | 1988-08-03 | — | — | EP | claimed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | claimed |
| EP-3548023-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D Therapeutics, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018102399-A1 | METHODS OF DOSE ADMINISTRATION FOR TREATING OR PREVENTING COGNITIVE IMPAIRMENT USING INDANE ACETIC ACID DERIVATIVES | T3D THERAPEUTICS, INC. (US) | 2018-06-07 | — | — | WO | disclosed |
| CN-105622470-A | Method for preparing sulfur containing indenone or derivatives thereof | UNIV WENZHOU | 2016-06-01 | — | — | CN | disclosed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| WO-2012074980-A2 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISORDERS AND LIVER DISORDERS USING INDANE ACETIC ACID DERIVATIVES | DARA BIOSCIENCES, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2200990-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| EP-1433781-B1 | Pyrrolidine carboxylic acid derivatives | MGI GP INC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| CN-1288464-A | 4- (2-keto-1-benzimidazolinyl) piperidine compounds as ORL-1 receptor agonists | PFIZER PHARMA (US) | 2001-03-21 | — | — | CN | disclosed |
| EP-1049689-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER INC. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999036421-A1 | 4-(2-KETO-1-BENZIMIDAZOLINYL)PIPERIDINE COMPOUNDS AS ORL1-RECEPTOR AGONISTS | PFIZER PHARMACEUTICALS INC. (JP) | 1999-07-22 | — | — | WO | disclosed |
| EP-0151702-B1 | ALPHA-HYDROXYKETONE ACETALS | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1987-11-25 | — | — | EP | disclosed |
| EP-0048136-B1 | PROCESS FOR PREPARING ALPHA-AROMATIC GROUP SUBSTITUTED ALKANOIC ACIDS OR ESTERS THEREOF | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1986-06-11 | — | — | EP | disclosed |
| US-4539420-A | Optically active 1-aromatic-group-substituted-1-alkanones and methods for their manufacture | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1985-09-03 | — | — | US | disclosed |
| EP-0151702-A2 | Alpha-hydroxyketone acetals | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1985-08-21 | — | — | EP | disclosed |
| EP-0067698-A2 | Optically active 1-aromatic-group-substituted-1-alkanones and methods for their manufacture | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-12-22 | — | — | EP | disclosed |
| EP-0048136-A2 | Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CEL 2282/4885DAO 3860/4885CYP11B2 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.